One of the most common complications of pregnancy is preeclampsia. Preeclampsia occurs in ~8% of all pregnancies, and is significantly more prevalent in specific ethnic subpopulations. 1 Despite an increasing awareness of the condition, and aggressive therapeutic intervention, preeclampsia remains a leading cause of both fetal and maternal perinatal morbidity and mortality, with ~15% of all preterm pregnancies attributable to preeclampsia. 2 The disease is primarily seen in nulliparous women, with a significantly decreased incidence in succeeding pregnancies. 3 Traditionally, the disorder has been defined by hypertension (systolic >140 mm Hg), proteinuria (300 mg/24 h), and edema. 4 However, current guidelines omit edema as a necessary symptom for diagnosis, and there is increasing discussion as to whether the absolute values of proteinuria are the correct metrics by which to guide treatment, or whether the protein/ creatine ratio would be a more diagnostic measurement. 5 Treatment of preeclampsia is problematic, and is mainly aimed to minimize the symptomatic complication of the disease. Prophylactic administration of magnesium sulfate to counteract the possibility of seizure in the most severe cases is common. Hypertension in more severe cases is managed by any of several antihypertensive agents, though full normalization of hypertension by pharmacological means is not feasible. In all cases the only means of full remission is delivery, not only of the fetus, but more importantly, the placenta. To illustrate, there have been reported cases in which delivery of the fetus without total delivery of the placenta failed to remit the maternal symptoms, implicating the placenta as the central causative agent in disease progression. Therefore, the ultimate goal of the treatment regimen is to prolong gestation as long as possible for maturity of the fetus and safe delivery. In the severest cases induction prior to 37 weeks gestation is necessary, with considerably increased risk of complications for the newborn. 4
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Origins Of PreeclamPsia
While the exact etiology which underlies preeclampsia is not clear, it is believed to originate from a fundamental error in the normal process of placentation. During a normal healthy pregnancy, a highly coordinated program ensures that the placenta and fetus are supplied with an adequate blood supply necessary for proper oxygen and nutrient delivery. Cytotrophoblasts originating from the fetus migrate into the maternal vasculature, and invade the maternal spiral arteries. These invasive trophoblasts gradually replace the endothelial lining of the vessels, undergoing a shift to an endothelial-like cell in the process. This normal program of invasive remodeling converts the normally low-capacitance, high-resistance vessels into highcapacitance, low-resistance vessels. This ensures adequate delivery of blood to the placenta, and thus the fetus. 6, 7 In the preeclamptic patient this coordinated program is significantly interrupted. Clues to the nature of the developmental abnormalities come from examination of the spiral arteries in the uterine myometrium. The normal remodeling of the spiral arteries does not occur, resulting in small, highly resistant, Endothelin: Key Mediator of Hypertension in Preeclampsia low-capacity vessels. 8 As a result of this failure to remodel, insufficient blood flow to the uteroplacental unit results. The placenta, which even in a normal pregnancy is a comparatively hypoxic organ, becomes extremely hypoxic; resulting in a dramatic increase in expression of hypoxia-inducible genes. [9] [10] [11] An interesting caveat to this model of the origin of preeclampsia is that there are reported instances in which deficient spiral artery remodeling fails to lead to a preeclamptic state. 12 The intriguing possibility is that there are additional factors which must be present in conjunction with the hypoxic placenta in order for full expression of the disease. Preeclampsia is therefore to be regarded as occurring in two distinct phases. In the first phase, the abovementioned errors in vascular remodeling set the stage for the placental ischemia/hypoxia which provides the stimulus for release of primary and secondary factors which lead to the second symptomatic phase, hallmarked by widespread by maternal endothelial dysfunction.
One area of intensive research in recent years has been the vascular endothelial growth factor (VEGF) signaling pathway, which is necessary for the maintenance of proper endothelial cell function and health. Specifically, much study has been given to the soluble secreted form of the VEGF receptor, soluble fms-like tyrosine kinase-1 (sFlt-1), which acts as a VEGF antagonist by binding free VEGF and making it unavailable for signaling to membrane bound receptors. 13 Circulating levels of sFlt-1 are significantly elevated in preeclamptic women when compared to healthy pregnant women, and elevated tissue levels of sFlt-1 are found in the placenta of preeclamptic women. 14, 15 Significantly, in an in vitro context, sFlt-1 is released from both placental explants and trophoblasts in response to decreased oxygen tension, suggesting a mechanism by which placental ischemia/hypoxia might lead to increased circulating sFlt-1. [16] [17] [18] Perhaps most importantly, infusion of sFlt-1 in rodents leads to preeclampsia-like phenotypes, with hypertension, renal injury, and proteinuria, and is now a commonly used experimental model of hypertension. 15, [19] [20] [21] [22] [23] [24] [25] It is now commonly understood that placental hypoxia and ischemia are the underlying source for vasoactive factors which are at the root of the symptomatic phase of the disorder. However, the mechanisms of endothelial dysfunction are still under investigation. One factor which has repeatedly been shown to play a crucial role in the development of hypertension in experimental animal models of placental hypoxia/ ischemia is the protein endothelin-1 (ET-1).
et-1 in PreeclamPsia
First characterized over 20 years ago, ET-1 was first identified as a potent endothelium-derived vasoconstrictor, the most potent vasoconstrictor known. 26 Derived from a longer 203-amino acid precursor known as preproendothelin, the active peptide proteolytically cleaved into its final 21-amino acid form. Numerous cardiovascular diseases have been shown to be associated with elevated ET-1 production, including hypertension, congestive heart failure, and chronic renal failure. [27] [28] [29] [30] Much of the research on ET-1 has focused on the role of the endothelin type A (ET A ) receptor, which is found in the vascular smooth muscle and are important regulators of ET-1 dependent vasoconstriction and cellular proliferation. 30, 31 However, there is another ET-1 receptor, the endothelin type B (ET B ) receptor which is found, among other locations, on vascular endothelial and renal epithelial cells. 28, 32, 33 In contrast to ET A receptor activation, agonism of ET B receptors conveys a vasodilatory response through the production of nitric oxide (NO) and cyclooxygenase metabolites. 34 The exact role of endothelin and the relative contributions of the ET A and ET B receptors to human disease are not fully elucidated though the system has shown great promise as a target for the treatment of cardiovascular disease. 35 Several lines of evidence, summarized in Table 1 , suggest a role for ET-1 as a pathophysiological factor in the development of preeclampsia. Multiple studies have examined circulating levels of ET-1 in normal pregnant and preeclamptic cohorts, and found elevated levels of plasma ET-1 in the preeclamptic group, with some studies indicating that the level of circulating ET-1 correlates with the severity of the disease symptoms, though this is not a universal finding. [36] [37] [38] [39] Coincidental with the increase in circulating ET-1, at least one group measured a significant negative correlation between ET-1 levels and the levels of the vasodilators NO and cGMP in preeclamptic women. 38 This increase in ET-1 can be partially attributed to an increased activity of the endothelin-converting enzyme in the circulation of preeclamptic women, which persists well into the postpartum period. 40 Concurrent infusion of ET-1 with the endothelin-converting enzyme inhibitor phosphoramidon shows differential effects in nonpregnant and normal pregnant 
Findings in Human Preeclampsia
References elevated circulating et-1 taylor et al, 36 baksu et al, 37 Nishikawa et al 38 Increased circulating endothelin converting enzyme (eCe) activity
Ajne et al 40 Differential effect of systemic eCe inhibition
Ajne et al 41 elevated localized et-1 production in maternal tissues Napolitano et al, 43 Faxen et al 44 The endothelin-1 (ET-1) system is altered in human preeclampsia. Numerous studies have examined the ET-1 system in preeclamptic women. Among the reported findings are elevated circulating levels of ET-1, increased endothelin converting enzyme activity in the circulation, elevated tissue production of preproET-1 mRNA, and differential response to ECE antagonism when compared to nonpregnant or healthy pregnant women. Relevant citations are reported here and in the text.
women vs. those with diagnosed preeclampsia. 41 There are also indications that at least in vitro, a secondary VEGF-dependent pathway for ET-1 induction occurs through the activity of matrix metalloproteinase-2 independently of endothelin-converting enzyme, though whether this pathway is physiologically relevant in preeclampsia is yet to be determined. 42 These differences in ET-1 levels have been implicated in increased contractility of the uterine arteries in an ex vivo experimental model. 39 In addition to increased circulating ET-1, there is a clear autocrine/paracrine role for ET-1, and examination of preproendothelin message levels in a variety of tissue beds from preeclamptic women has demonstrated increased local production, suggesting a further role in the etiology of the disease. 43, 44 Finally, when placental explants from healthy pregnancies are incubated with exogenously applied ET-1, they demonstrate a significant increase in the expression of markers for oxidative stress, which has been shown to be an important effector for the widespread maternal endothelial dysfunction and hypertension associated with preeclampsia. Furthermore, ET-1 caused a decrease in the proliferation of JEG-3 cells, a commonly used trophoblast cell line, leaving open the possibility that ET-1 plays a role in the failure of trophoblast invasion in the early stages of preeclampsia. 45 
et-1 in exPerimental Pregnancy-induced HyPertensiOn Placental ischemia/hypoxia
In recent years, several excellent animal models of experimental preeclampsia have been developed. 25 One which has proven to mimic many of the hallmarks of preeclampsia is the reduced uterine perfusion pressure (RUPP) model. In this model, blood flow to the uterus is partially occluded during the later stages of gestation, resulting in severe placental hypoxia and ischemia. This model has been recapitulated in rodent, canine, and nonhuman primates, with hypertension, elevated sFlt-1, endothelial dysfunction, renal injury, and resulting proteinuria being common findings. [46] [47] [48] Initial findings in the rodent RUPP model demonstrated that both the cortical and medullary concentrations of preproendothelin mRNA were significantly elevated when compared to healthy pregnant controls, as assayed by RNAse protection assays.
Moreover, though administration of an ET A specific antagonist had no effect on normal pregnant animals, in the RUPP treated animals, the associated hypertension was completely normalized by ET A antagonism. Further, though not statistically significant, effective renal plasma flow was decreased in the RUPP treated rats, which was normalized in those treated with ET A receptor blockade. 49 Follow-up studies utilizing human umbilical vein endothelial cells and sera from RUPP treated rats demonstrated that ET-1 release was stimulated by RUPP serum when compared to serum obtained from normal pregnant rats. 50 It is clear then that the hypertension seen in the RUPP placental ischemia/hypoxia model is heavily dependent on increased ET-1 production and signaling through the ET A receptor.
angiogenic imbalance
The role of ET-1 signaling in the rodent sFlt-1 infusion model of pregnancy induced hypertension has also been studied. Several reports have emerged that in pregnant rats, recombinant sFlt-1 or adenoviral delivery of the protein result in significant hypertension, proteinuria, and endothelial dysfunction. 15, 19, 20 A recent report demonstrated that the administration of sFlt-1 to pregnant rats also significantly increases the production of preproendothelin message levels in the renal cortex. As a result of sFlt-1 infusion in this model, mean arterial pressure is increased ~20 mm Hg. With coadministration of an ET A antagonist however, this hypertensive response was completely abolished. 20 In a related study, one group has reported that administration of the compound suramin elicits a preeclampsia-like phenotype. Suramin is a potent anti-angiogenic compound thought to inhibit, among other things, VEGF. In this model of hypertension, circulating levels of ET-1 are significantly elevated, demonstrating again the importance of VEGF signaling in the maintenance of a healthy endothelium. 51 As it has been shown that VEGF signaling through the VEGFR2 receptor is important for the production of endothelium-derived NO, it is likely that one mechanism by which sFlt-1 induces hypertension in the pregnant rat is by decreasing the amount of bioavailable NO, thereby increasing systemic peripheral resistance. 52 Whatever the mechanism or mechanisms involved, it seems clear that the hypertension associated with angiogenic imbalance, namely loss of bioavailable VEGF, is heavily reliant on the production of ET-1, showing again its importance in the development of preeclampsia.
autoimmunity and inflammatory factor administration
There is a growing realization that autoimmunity plays in important role in the symptoms, and perhaps the origins, of preeclampsia. [53] [54] [55] Included in this broad heading are two separate, but equally important maternal responses; the innate autoimmune response mediated by inflammatory cytokines and the production of agonistic autoantibodies to the angiotensin II type-1 receptor (AT1-AA). The recognition of these pathogenic pathways has given rise to several new animal models of experimental gestational hypertension, and once again implicated ET-1 production as a central agent in the disease progression.
One of the best characterized inflammatory cytokines known to be elevated in the circulation of preeclamptic women is tumor necrosis factor-α (TNF-α). TNF-α has been shown to be elevated not only in preeclamptic women, but also at comparable levels in the circulation of RUPP-induced rodents. [56] [57] [58] Downloaded from https://academic.oup.com/ajh/article-abstract/24/9/964/215653 by guest on 16 February 2018 Intriguingly, administration of the soluble TNF-α receptor Etanercept resulted in the partial abrogation of RUPP-induced hypertension. Coincidentally, tissue expression of preproendothelin was significantly reduced with Etanercept administration, suggesting that ET-1 expression is at least partially driven by increases in TNF-α. 58 In order to study the importance of TNF-α in the progression of preeclampsia, a model of TNF-α infusion has been developed in rodents. 25 In response to TNF-α infusion, pregnant rats demonstrate ~20 mm Hg increase in mean arterial pressure. There was also a concomitant increase in the expression of preproendothelin expression in the aorta, placenta, and renal tissue from TNF-α infused rats. Indeed, coadministration of an ET A receptor antagonist completely abolished the hypertensive response to TNF-α infusion. As an intriguing side, TNF-α infusion had no significant effect on blood pressure or preproendothelin expression in virgin rats, suggesting that pregnancy conveys a heightened sensitization to circulating TNF-α. 59 This data is consistent with earlier in vitro data which demonstrated that ET-1 expression from endothelial cells is regulated in part by TNF-α signaling. 60 Whatever the additional factors involved in TNFα-induced hypertension during pregnancy, it appears clear that endothelin signaling plays an important role in the symptomatic consequences of this pathway.
One of the most intriguing aspects of preeclampsia to emerge in recent years is the identification of the circulating AT1-AA. Originally identified in the circulation of preeclamptic patients, these circulating autoantibodies have been shown to induce reactive oxygen production in vitro, and there appears to be a direct correlation between the level of the AT1-AA and sFlt-1 in preeclamptic women. 61, 62 The production of the AT1-AA seems to be directly related to placental ischemia through the induction of TNFα, as the autoantibody appears in the circulation of both the RUPP rat and the TNFα infusion model at levels approximately equal to those of preeclamptic women. 63 In follow-up studies, it was demonstrated that infusion of the purified AT1-AA into pregnant rats resulted in an ~20% increase in the mean arterial pressure. Analysis of tissue expression of preproendothelin levels showed a dramatic increase in expression, showing that AT1 receptor activation by AT1-AA could play a critical role in ET-1 production during preeclampsia. Again, pharmacologic blockade of the ET A receptor completely abolished the hypertensive response to AT1-AA infusion, demonstrating yet again that ET-1 is a central agent in the pathology of preeclampsia. 64 
et-1: a possible therapeutic target?
It appears clear that ET-1, specifically acting through the ET A receptor, plays an important role in the etiology of preeclampsia. As seen in Figure 1 , multiple mechanisms, all mediated by placental ischemia, induce ET-1 expression. Experimentally, ET-1 antagonism in each of these models can reduce the pathophysiological hypertension. Is this then a potential target for therapeutic intervention? A great of consternation has surrounded ET A blockade during pregnancy due to the fact that ET A receptor deletion in mice has proven to cause birth defects and embryonic lethality in mice, and the administration of endothelin receptor antagonists is contraindicated during pregnancy. 65, 66 However, succeeding studies in which pharmacological blockade of the receptor initiated throughout gestation identified specific times in early to mid-gestation which resulted in phenotypical birth defects similar to those seen in the knockout model. ET A blockade during mid-gestation was implicated as the pivotal window for the previously characterized birth defects, as administration of the antagonist before and after mid-gestation resulted in differential effects. Administration only in late pregnancy was not performed, so the exact effect of ET A blockade only in late pregnancy is not clear. 67 The possibility remains that ET A receptor antagonists might be successfully administered in later gestation to control the most severe symptoms of preeclampsia. Research into the safety and efficacy of ET A receptor blockade during pregnancy and preeclampsia is warranted, and may provide an effective target for this complicated and difficult disorder. 
Placental ischemia
Hypertension ET-1 TNF-α AT1-AA sFlt-1/ VEGF figure 1 | placental ischemia induces endothelin-1 (et-1) expression through multiple pathways during preeclampsia. As a result of placental ischemia, soluble fms-like tyrosine kinase-1 (sFlt-1) is increased in the circulation, directly antagonizing vascular endothelial growth factor (VeGF). Circulating levels of tumor necrosis factor-α (tNF-α) and the agonistic angiotensin II type-1 receptor auto-antibody (At1-AA) are increased. each of these pathways in turn increase et-1 production resulting in maternal hypertension.
